From Promise to Reality: Advancing Cell Therapies Beyond Oncology

The 4th Cell Therapy for Autoimmune Disease Summit returns to Philadelphia at a time when treatment of autoimmune disease is quickly becoming the most exciting new area of focus for cell therapy drug developers. With renewed pharma interest from teams like Moderna and clinical data across autologous, allogeneic, and in vivo approaches expected at any time, this is an exciting area to follow. This year’s summit will bring together pioneering biotech, pharma, and academic leaders to explore the latest advances across lupus, multiple sclerosis, rheumatoid arthritis, and rare autoimmune indications.

Following this wave of breakthrough clinical proof-of-concept studies, the focus now shifts to scaling these therapies across indications and continuing to demonstrate safe and efficacious treatments that go beyond treating symptoms and towards true cures. As developers head toward commercially viable, disease-modifying therapies, the field must now address the challenges of safety, scalability, durability, and patient access.

Beyond the scientific progress, the meeting provides a rare opportunity to engage with a community entirely focused on advancing cell therapies for autoimmune disease. The two-track structure of the meeting, covering Preclinical Development & Translation and Clinical Development, creates a collaborative environment for sharing experiences, challenging assumptions, and building relationships. The result is more relevant conversations and stronger connections than are typically possible at broader industry events.